| Download | - View final version: Tuning the immune response: sulfated archaeal glycolipid archaeosomes as an effective vaccine adjuvant for induction of humoral and cell-mediated immunity towards the SARS-CoV-2 Omicron variant of concern (PDF, 2.9 MiB)
|
|---|
| DOI | Resolve DOI: https://doi.org/10.3389/fimmu.2023.1182556 |
|---|
| Author | Search for: Renner, Tyler M.1; Search for: Akache, Bassel1; Search for: Stuible, Matthew1; Search for: Rohani, Nazanin1; Search for: Cepero-Donates, Yuneivy1; Search for: Deschatelets, Lise1; Search for: Dudani, Renu1; Search for: Harrison, Blair A.1; Search for: Baardsnes, Jason1; Search for: Koyuturk, Izel1; Search for: Hill, Jennifer J.1; Search for: Hemraz, Usha D.2; Search for: Régnier, Sophie2; Search for: Lenferink, Anne E. G.1; Search for: Durocher, Yves1; Search for: McCluskie, Michael J.1 |
|---|
| Affiliation | - National Research Council of Canada. Human Health Therapeutics
- National Research Council of Canada. Aquatic and Crop Resource Development
|
|---|
| Format | Text, Article |
|---|
| Subject | sulfated archaeal glycolipid (SLA); archaeosome; adjuvant; SARS-CoV-2; spike subunit vaccine; omicron; AddaS03; variants of concern (VOC) |
|---|
| Abstract | Liposomes composed of sulfated lactosyl archaeol (SLA) have been shown to be a safe and effective vaccine adjuvant with a multitude of antigens in preclinical studies. In particular, SLA-adjuvanted SARS-CoV-2 subunit vaccines based on trimeric spike protein antigens were shown to be immunogenic and efficacious in mice and hamsters. With the continued emergence of SARS-CoV-2 variants, we sought to evaluate next-generation vaccine formulations with an updated antigenic identity. This was of particular interest for the widespread Omicron variant, given the abundance of mutations and structural changes observed within its spike protein compared to other variants. An updated version of our resistin-trimerized SmT1 corresponding to the B.1.1.529 variant was successfully generated in our Chinese Hamster Ovary (CHO) cell-based antigen production platform and characterized, revealing some differences in protein profile and ACE2 binding affinity as compared to reference strain-based SmT1. We next evaluated this Omicron-based spike antigen for its immunogenicity and ability to generate robust antigen-specific immune responses when paired with SLA liposomes or AddaS03 (a mimetic of the AS03 oil-in-water emulsion adjuvant system found in commercialized SARS-CoV-2 protein vaccines). Immunization of mice with vaccine formulations containing this updated antigen with either adjuvant stimulated neutralizing antibody responses favouring Omicron over the reference strain. Cell-mediated responses, which play an important role in the neutralization of intracellular infections, were induced to a much higher degree with the SLA adjuvant relative to the AddaS03-adjuvanted formulations. As such, updated vaccines that are better capable of targeting towards SARS-CoV-2 variants can be generated through an optimized combination of antigen and adjuvant components. |
|---|
| Publication date | 2023-04-14 |
|---|
| Publisher | Frontiers |
|---|
| Licence | |
|---|
| In | |
|---|
| Language | English |
|---|
| Peer reviewed | Yes |
|---|
| Export citation | Export as RIS |
|---|
| Report a correction | Report a correction (opens in a new tab) |
|---|
| Record identifier | 428341a5-f5a6-48bf-acd7-1d491def58a7 |
|---|
| Record created | 2023-06-06 |
|---|
| Record modified | 2023-06-06 |
|---|
